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Several mechanisms involved in ingestive behavior and neuroendocrine activity rely on vagal afferent neuronal signaling. Seemingly
contradictory to this idea are observations that vagal afferent neuronal ablation by neonatal capsaicin (CAP) treatment has relatively small effects
on glucose homeostasis and long-term regulation of energy balance. It may be proposed that humoral endocrine factors and/or their sensitivities
compensate for the loss of vagal afferent information, particularly when subjects face disturbances in ambient fuel levels. Therefore, male adult
rats neonatally treated with CAP or with the vehicle (VEH) underwent intravenous glucose tolerance tests (IVGTTs) during which blood fuel
levels, and circulating adipose, pancreatic, and adrenal hormones were assessed. CAP rats displayed similar hyperglycemia as VEH rats, but with
markedly reduced plasma insulin and corticosterone responses. These results indicate that CAP rats have increased insulin sensitivity during
hyperglycemic episodes, and lower plasma levels of corticosterone in CAP rats relative to VEH rats could underlie this effect. After the IVGTT,
CAP rats had increased plasma adiponectin and reduced plasma resistin levels, and these alterations in adipose hormones might be relevant for
post-ingestive metabolic processes. In a second experiment, anorexigenic efficacies of cholecystokinin and leptin were assessed. While VEH rats,
but not CAP rats, responded with reduced food intake to i.p. injected cholecystokinin, only CAP rats responded to i.v. infused leptin with a
reduction in food intake. It is concluded that reduced HPA axis activity and/or increased leptin signaling could underlie compensations in fuel
handling and energy balance following CAP treatment.
© 2006 Elsevier Inc. All rights reserved.Keywords: IVGTT; leptin; adiponectin; corticosterone; FFA; melanocortin; CCK; vagal afferents1. Introduction
Energy homeostasis is maintained by an array of biochem-
ical and physiological mechanisms that help to ensure the
constancy of the internal environment under varying nutritional
conditions and energy demands. An important component of the
underlying regulatory processes consists of peripheral informa-
tion regarding the energetic status which is conveyed via vagal
neuronal afferents to the CNS. In turn, these signals are relayed
in CNS neuronal networks where they play a role in the sen-
sation of hunger and satiety as well as in the regulation of
neuroendocrine control of energy homeostasis [1].
With the advent of capsaicin (CAP)–a pungent ingredient of
red peppers which selectively destroys primary C-afferents and⁎ Corresponding author. Tel.: +31 50 3632116; fax: +31 50 3632331.
E-mail address: gertjan.van.dijk@rug.nl (G. van Dijk).
0031-9384/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.physbeh.2006.03.018small myelinated Aδ-afferents (for review see [2,3])–a phar-
macological tool became available to study the effect of ablation
of vagal primary afferents on regulation of energy balance.
CAP-treated animals have disturbances in short-term satiety
signaling and do not respond to cholecystokinin (CCK) with
reduced food intake [4–6]. However, CAP-treated rats have
similar daily food intake [7], similar or even lower body weight
[8] and improved glucose homeostatic control [17] compared to
controls. Furthermore, deafferentated animals have a long-term
decrease in white adipose tissue mass [9] and are more resistant
to ageing-associated obesity [10]. Finally, CAP treatment re-
sults in increased whole body insulin sensitivity [11] and a
lower degree of ageing-associated insulin resistance [10]. These
observations indicate that CAP-treated animals are able, or even
have improved capability, to maintain body weight and energy
homeostasis, despite the fact that they lack seemingly important
information transmitted via vagal afferents to the CNS. To date,
the underlying mechanisms are poorly understood.
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regulation of ingestive behavior, energy homeostasis, and body
weight maintenance consists of endocrine/hormonal factors
which are released into the blood stream and affect enzymatic/
endocrine processes and metabolic fluxes in various peripheral
organs and tissues [12]. In addition,most of these factors can enter
the CNS where they alter the activity of neuronal circuitry in-
volved in ingestive behavior, neuroendocrine outflow and me-
tabolism [12]. One hypothesis pertinent to the observations that
CAP-treated rats are able to maintain body and energy ho-
meostasis might be that vagal afferent ablation is compensated by
these redundant endocrine factors involved in the regulation of
energy homeostasis and ingestive behavior. To investigate this
hypothesis, the concentration of blood fuels (i.e., plasma glucose
and free fatty acids) and circulating hormones involved in blood
glucose regulation and ingestive behavior (i.e., insulin, leptin,
adiponectin, resistin and corticosterone) were investigated in
overnight fasted rats that were neonatally treated with CAP or
with the vehicle (VEH). In addition, the changes in these blood
parameters were assessed during and after an intravenous glucose
tolerance test (IVGTT). In a second experiment, anorexigenic
efficacies of CCK, leptin, and the synthetic melanocortin (MC)
receptor-agonist, melanotan II [13], were assessed in CAP and
VEH rats. The latter study was performed since theMC4 receptor
is implicated in the leptin signaling cascade [14].
2. Materials and methods
2.1. Animals and housing
Twenty-eight male Wistar rats from the breeding facility of
our university were used and housed in climate-controlled
rooms (22±2 °C) under a 12-h:12-h light–dark cycle (lights on
at 8:00 a.m.). Food and water were ad libitum available, unless
mentioned otherwise. All experiments were checked and ap-
proved by the Local Ethics Committee of our university.
2.2. Capsaicin treatment
Rats were treated neonatally with CAP (8-methyl-N-vallinyl-
6-nonenamide, 50 mg/kg; Sigma Chemical, The Netherlands) at
the age of day 2 (n=14) by subcutaneous (s.c.) injection. This
was done under 100% O2 conditions to avoid hypoxia. CAP
was dissolved in vehicle consisting of 10% ethanol (10%) and
5% cremophore–0.9% sodium chloride solution (90%). As a
control, VEH solution was injected s.c. (n=14). Each animal
was given the same volume of 50 μl based on an average weight
of the pups of 8 g. At injection, both groups did not differ
significantly in body weight (CAP 8.84±0.20 g; VEH 8.32±
0.23 g). CAP-treated and VEH-treated pups grew up se-
parately–to avoid selective mother care–in litters of 5–9 pups,
in the proportion of 5–7 male on 2 females (untreated). After
weaning at the age of 23 days, rats were individually housed in
clear Plexiglas cages (25×25×30 cm) with a bedding of
sawdust. Following treatments, body weights were assessed at
days 34, 58, and thereafter, every 10 days until experiments. An
eye-wipe response (0.1% capsaicin solution) was done at theage of 3 months in order to test the effectiveness of the CAP
treatment. As opposed to the VEH controls, none of the neo-
natally CAP-treated animals responded to the test and all ani-
mals were therefore included in the experiment.
2.3. Surgery
After the eye-wipe test, 16 animals were implanted with
double heart catheters in the left and right jugular veins according
to techniques described by Steffens [15]. An additional 12 ani-
mals were provided with heart catheters only in the right jugular
vein according to the same techniques. Surgery was performed
under anaesthesia with isoflurane/N2O/O2. Fynadine (0.01 ml/
100 g body weight) was given s.c. as post-surgical analgesia.
Animals had at least 2 weeks of recovery before the start of
experiments.
2.4. Intravenous glucose tolerance test (IVGTT)
Body weights did not differ significantly between both
groups (CAP: 403±7.7; VEH: 410±10.9). Overnight food-
deprived CAP (n=8) and VEH-treated rats were subjected to an
IVGTT, which was performed in the light period between 12:00
a.m. and 1:00 p.m. At least half an hour before the start of the
IVGTT, rats were connected with their indwelling cannulae to
blood sampling (right jugular catheter) and infusion (left jugular
catheter) tubing. These tubes extended out of the rats' cages,
which allowed stress-free blood sampling and/or intravenous
infusion. After taking two basal blood samples at t=−11 and t=
−1 min, a glucose solution (15% dissolved in sterile demin-
eralized water) was infused over a 30-min period at a rate of
15 mg/min (450 mg total). Additional samples were taken at
t=1, 3, 5, 10, 15, 20, 25, 30, 40, 50 min in order to assess blood
glucose and plasma insulin. In general, samples consisted of
0.2 ml whole blood for assessment of blood glucose (50 μl) and
plasma insulin (50 μl) levels. At t=−11, t=30, and t=50, an
additional 0.2 ml of blood was taken for determination of
plasma levels of adiponectin (3 μl), leptin (30 μl), resistin
(30 μl), corticosterone (10 μl), and free fatty acids (FFAs,
10 μl). Blood and plasma samples were stored at −20 °C until
analysis. Blood glucose levels were measured by the ferricy-
anide method of Hoffman; plasma levels of insulin, adiponectin,
leptin, resistin and corticosterone were measured by commercial
radioimmunoassay kits (Linco Research, Nucli lab, The
Netherlands), and plasma levels of FFAs were assessed with a
NEFA C enzymatic kit (WAKO Chemicals GmbH, Germany).
2.5. Anorexigenic efficacies of CCK, leptin and melanotan-II
In another group of CAP- (n=4–6) and VEH-(n=4–6)-
treated rats, the anorexigenic efficacies of CCK, leptin, and the
synthetic melanocortin 3/4 receptor agonist, melanotan-II were
assessed. Therefore, rats' food hoppers were removed from their
home cages 2 h before lights off. In a counterbalanced design,
and with 5 days elapsing between successive experiments, rats
were i.v. infused between 30 and 15 min before lights off
solutions containing leptin (70 μg/250 μl saline, Calbiochem,

















Fig. 1. Effects of neonatal capsaicin (CAP) treatment and vehicle (VEH)
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and 160 μg/kg in CAP-treated rats), melanotan-II (50 μg/250 μl
saline, Sigma Chemical, The Netherlands; this dose corre-
sponds to 118 μg/kg in control animals and 114 μg/kg in CAP-
treated rats), or with saline (250 μl) only. After all treatments,
food hoppers were returned to the cages at lights off, and
cumulative food intake was assessed at 1, 2, and 4 h in the dark
phase. In other tests, but under similar experimental conditions,
these animals were i.p. injected with saline (250 μl) or with
saline containing CCK (4 μg/kg Sigma Chemical, The Nether-

































Fig. 2. Blood glucose and plasma insulin levels before, during, and after an
IVGTT consisting of a 15% glucose infusion infused over 30 min in adult male
Wistar rats, which were neonatally treated with capsaicin (CAP) or vehicle
(VEH). ⁎ and ⁎⁎, pb0.05 and pb0.01, respectively.lation is known to impair peripheral actions of CCK on
ingestive behavior [4–6], this latter comparison was performed
as a positive control for CAP treatment. Seven animals of each
group were decapitated (non-fasted) at the end of the exper-
iment and weights of fat pads (retroperitoneal and epididymal
fat) and liver as well as basal plasma leptin levels were assessed.
2.6. Statistical analysis
Data are presented ± the standard error of the mean (S.E.M.).
Analysis of variance (ANOVA) with repeated measurements
was performed for statistical evaluation with time (sampling
points) as within-subject factor and group (CAP or VEH) as


































Fig. 3. Circulating adipocyte factors leptin, adiponectin and resistin before,
during, and after an IVGTT consisting of a 15% glucose infusion infused over
30 min in adult male Wistar rats, which were neonatally treated with capsaicin
































Fig. 4. Plasma corticosterone levels and free fatty acid (FFA) levels before,
during, and after an IVGTT consisting of a 15% glucose infusion infused over
30 min in adult male Wistar rats, which were neonatally treated with capsaicin






































































Fig. 5. Effects of cholecystokinin (CCK), leptin and melanotan-II (MTII) on
food intake in adult male Wistar rats which were neonatally treated with
capsaicin (CAP) or vehicle (VEH). ⁎, ⁎⁎, and ⁎⁎⁎, pb0.05, 0.01, and 0.001,
respectively.
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testing was performed from sampling point −11 or −1 min till
sampling point 30 min at the end of the glucose infusion. One-
sided Student's t-test was used for unpaired observations. A
value of p≤0.05 was considered significant for all tests.
3. Results
Body weights of CAP and VEH rats are shown in Fig. 1.
AlthoughCAP rats appeared slightly lighter thanVEH rats, there
were no significant differences over time. In VEH and CAP rats,
epididymal fat pad weights (8.9±0.8 g and 7.5±0.9 g, res-
pectively), retroperitoneal fat pad weights (2.6±0.3 g and 2.0±
0.5 g, respectively), liver weights (16.5±0.7 g and 15.5±1.4 g,
respectively), and plasma leptin levels (3.95±0.79 ng/ml and
3.54±1.12 ng/ml, respectively) did not differ significantly.
3.1. Intravenous glucose tolerance test (IVGTT)
Fig. 2 shows the changes in blood glucose and plasma insulin
levels before, during, and after the 30-min intravenous glucose
infusion. ANOVAwith repeated measurements revealed signif-
icant effects of time on plasma levels of insulin and glucose
(F8,112=40.6, pb0.001 and F8,80=66.7, pb0.05, respectively).
There was no significant time×group interaction for insulin
(F8,112=1.7, p=0.11) or glucose (F8,80=0.46, p=0.88). Therewas a significant group effect on plasma insulin levels during
glucose infusion (F1,14=4.9, pb0.05), but blood glucose levels
did not differ significantly between CAP and VEH (F1,10=0.46,
p=0.51). This difference in insulin response was particularly
clear at t=1 min, which is considered as the first-phase insulin
response (CAP=4.55±0.43, VEH=7.03±0.71, pb0.01).
Fig. 3 shows changes in the plasma concentrations of the
adipocyte hormones leptin, adiponectin, and resistin at t=−1,
30 and 50 min. At baseline (t=−1), none of the assessed levels
of these hormones differed among CAP en VEH, and these
levels were not different during glucose infusion either.
However, after cessation of glucose infusion (t=50 min), the
plasma adiponectin level of CAP rats was significantly higher
(pb0.05) than that of VEH rats. In contrast, plasma resistin was
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(pb0.05). Plasma levels of leptin were not different in CAP and
VEH rats (F1,13=2.12, p=0.17). Fig. 4 shows the changes
observed in plasma concentrations of corticosterone and FFAs.
In VEH controls, plasma levels of corticosterone were increased
as a result of glucose infusion, but this effect was not observed
in CAP rats. Thus, plasma levels of corticosterone in CAP rats
were significantly lower (pb0.01) than in VEH rats at
t=30 min. During glucose infusion, plasma levels of FFAs
were reduced in both groups relative to baseline. After infusion,
there was a partial rebound in VEH rats, but not in the CAP rats.
Thus, plasma FFAs were significantly reduced at t=50 min
(pb0.05) in CAP rats relative to VEH controls.
3.2. Anorexigenic efficacies of CCK, leptin and melanotan-II
Fig. 5 shows the effect of i.v. infusion of leptin and MTII
relative to saline treatment, and of i.p. injection of CCK relative
to saline treatment on food intake. CCK caused a significant
reduction in food intake relative to saline treatment in VEH
controls (pb0.05) during the first hour of the dark phase, and a
tendency to reduce food intake during the second hour. These
effects were not observed in CAP rats. In contrast, i.v. leptin
infusion appeared to be effective over the first 2 h in the dark
phase only in CAP rats (pb0.05), but not in VEH rats. This
effect was mostly due to the fact that the leptin-treated CAP rats
did not have food intake during the second hour, whereas food
intake over the first hour was similar as in VEH rats. Finally, i.v.
infusion of MTII was equally effective in reducing food intake
over the full 4-h period in CAP and VEH rats. Interestingly,
MTII was more effective to reduce food intake over the first
hour in VEH rats than in CAP rats (pb0.01).
4. Discussion
Vagal afferent ablation in rats by neonatal capsaicin (CAP)
treatment has been shown in other studies to be ineffective [8],
or in some cases even preventive [10] of causing disturbances in
energy balance and glucose homeostasis. Since vagal afferents
are thought to serve important homeostatic functions [16], the
present study was designed to investigate the hypothesis that
neonatal CAP treatment results in compensatory adjustments by
redundant endocrine factors involved in the regulation of energy
balance and glucose homeostasis. Important for consideration
of the data in the present study is that body weights of our CAP
and VEH rats were not different, nor were there any overt
differences in weights of organs and tissues relevant to nutrient
balance. Basal (i.e., non-fasted) plasma leptin levels did not
differ between CAP and VEH animals either.
Consistent with a seemingly normal regulation of energy
balance was the observation that CAP- and VEH-treated rats had
indistinguishable fasting levels of adipocyte (i.e., leptin,
adiponectin, and resistin), pancreatic (i.e., insulin) and adrenal
(i.e., corticosterone) hormones; i.e., all factors known to corre-
late strongly with changes in energy balance. A different picture
emerged when viewing the data obtained with the IVGTT. Thus,
whereas the IVGTT caused similar increments in blood glucoselevels in CAP and VEH rats, the plasma insulin response was
markedly reduced in CAP rats relative to that in VEH-treated
controls. These data confirm our previous findings in non-fasted
CAP and VEH rats challenged with different glucose loads,
yielding similar dose-dependent elevations in blood glucose
levels, but with much lower plasma insulin responses in CAP
rats relative to those seen in VEH rats [17]. While the reduced
glucose-mediated insulin response in CAP rats might be the
result of absence of tonic activation of vagal afferents by gut
hormones [17,18], one implication of these findings is that CAP
rats are more insulin-sensitive than VEH controls. This idea is in
agreement with the findings of Koopmans et al.[11], who ob-
served increased whole body insulin action in CAP rats under
euglycemic hyperinsulinemic clamp conditions.
Humoral factors that stimulate insulin-dependent glucose
uptake are leptin and adiponectin [19] in a variety of tissues,
whereas corticosterone [20], resistin [21] and FFAs [22,23] have
the opposite effects. Among these, only the plasma level of
corticosterone was significantly different in CAP and VEH rats
at the end of the IVGTT. More specifically, the IVGTT led to an
increase in the plasma corticosterone level in the VEH rats, but
this effect was not observed in CAP rats. Although we have not
performed a full analysis of plasma corticosterone levels over the
course of the IVGTT, it might be possible that this reduced
plasma corticosterone level underlies the increased insulin
sensitivity in CAP rats. A lower corticosterone response in CAP
rats was previously observed by Koopmans et al. [11], and,
together with the data in the present study, this suggests a role for
vagal afferents and/or sensory nerves in the activation of the
HPA axis during hyperglycemia. It seems likely that vagal
afferents normally convey stimulatory actions of gut hormones,
such as CCK, on HPA axis activity [24]. These effects might be
amplified under hyperglycemic condition, analogous to the
mechanism underlying stimulated insulin secretion [18]. Such a
dependency on hyperglycemia would be consistent with the
finding in the present study that the difference in plasma
corticosterone levels in CAP and VEH rats disappeared as rats
regained normoglycemia after the IVGTT. After cessation of the
IVGTT, blood glucose, plasma insulin and corticosterone levels
returned to normal, but a higher plasma adiponectin and lower
resistin levels in CAP rats relative to VEH controls was found at
this stage. It might be possible that the transiently different
plasma corticosterone levels in CAP andVEH rats contributed to
these effects [25,26] but additional or more important factors are
not ruled out. While it is unlikely that the changes in adiponectin
and resistin levels contributed to the differences in glucose-to-
insulin indexes during the preceding IVGTT, they might have a
major impact on successive excursions of blood glucose or on
the metabolic consequences of these. In fact, the lower level of
plasma FFA in CAP rats after the IVGTT might be a direct
consequence of elevated plasma adiponectin levels and/or
reduced plasma resistin levels in these animals. Indeed,
adiponectin has been shown to stimulate muscle fatty acid
transporter [27] and to increase oxidation of FFA in skeletal
muscle [28]. This would result in accelerated FFA clearance
from the blood. A link between circulating FFAs and resistin is
less clear, but correlation analysis in mice suggests an interaction
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well as with obesity and insulin resistance [29]. Our results are in
agreement with Spiridonov and Vorobeva [30], who also reports
decreased FFA levels after neonatal treatment. Typically, higher
levels of FFA are associated with disturbances in glucose
homeostatic mechanisms [31] and this could mean that
decreased levels of FFA contribute to the enhanced glucose
disposal in CAP rats in following fuel excursions.
Despite the observed changes in adiponectin, resistin, and
corticosterone responses, there was no effect of the IVGTT on
the plasma levels of leptin, nor were there any differences
between the plasma leptin levels of CAP and VEH rats at
baseline. One idea that we addressed was the possibility that
CAP treatment increases leptin signaling. Whereas injection of
CCK, dosed to cause a reduction in food intake in VEH rats, did
not have any effect in CAP rats in the present study (and
confirming previous reports by [4–6], we observed that pe-
ripherally infused leptin caused a reduction in food intake in the
CAP rats, but failed to do so in VEH rats. These effects were
particularly pronounced over the second hour of the dark phase;
i.e., after the rats had eaten their first meals. Important for
consideration of the effects of peripherally elevated levels of
leptin is that these can be signaled directly in the CNS (i.e.,
through increased transport of leptin across the blood–brain
barrier) and additionally via vagal afferent fibers [32–34]. Since
CAP rats lack a substantial part of their vagal afferent inner-
vation, yet have an increased sensitivity to leptin with respect to
food intake modulation, it is likely that leptin's enhanced an-
orexigenic actions are mediated via interaction with CNS
pathways. Actions of leptin on ingestive behavior are mediated
through neural networks among which the brain melanocortin
(MC) system might be most relevant [35]. Since CAP rats had a
slightly lower anorexigenic response to the brain-specific me-
lanocortin receptor agonist, melanotan-II, than VEH rats (pre-
sumably due to compensatory actions), the difference between
leptin sensitivity in VEH and CAP rats is either located up-
stream from brain MC receptors or requires changes in neuronal
circuitry parallel to the brain MC system.
Provided that the augmented anorexigenic effects of leptin
are coincided with the altered neuroendocrine and metabolic
actions of leptin [12], this could possibly have contributed to the
lower plasma levels of corticosterone [36] and resistin [37] and
the elevated plasma level of adiponectin [38] in CAP rats. On
the other hand, a lower level of circulating glucocorticoids
might have contributed to the increased leptin signaling by
hypothalamic neuronal networks [39] in CAP-treated rats. In
fact, a reduction in glucocorticoid levels could underlie the
“healthier” endocrine and metabolic profile of the CAP rats in
the present study, since removal of adrenals resulting in other
studies has been shown to increase insulin sensitivity and me-
tabolism and reduce body weight gain even in rats which have a
deficient leptin signaling system [40–42].
This study shows that neonatal CAP treatment results in
endocrine, metabolic, and probably neuronal adjustments which
serve to maintain energy balance and glucose homeostasis in
these animals. At present, we do not know whether these ad-
justments have occurred early in life (i.e., in the days followingCAP treatment in the neonatal stage) and whether they are
perhaps not observed when CAP is applied in adult animals. In
summary, neonatal CAP treatment had, in adult animals, primary
inhibitory effects on plasma corticosterone levels, which could
have contributed to augmented insulin action during hypergly-
cemia. Secondary effects on plasma adiponectin and resistin
levels unlikely contributed to these effects, but could have major
consequences on post-ingestive metabolism or successive fuel
excursions. While these effects were correlated to increased
leptin sensitivity (with food intake suppression as read-out pa-
rameter), it remains to be investigated whether increased leptin
signaling is a consequence or a cause of these effects. As such,
this sort of interactions might have major implications for the
aetiology of obesity and diabetes because these diseases are
often characterized by dysregulation of the hypothalamic–pi-
tuitary–adrenal axis [43], as well as of altered adipocyte hor-
mone secretion and signaling [44,45].
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